Atomoxetine hydrochloride (cas 82248-59-7) in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study
-
Add time:07/21/2019 Source:sciencedirect.com
ObjectiveThe primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support.
We also recommend Trading Suppliers and Manufacturers of Atomoxetine hydrochloride (cas 82248-59-7). Pls Click Website Link as below: cas 82248-59-7 suppliers
Prev:Determination of the enantiomer and positional isomer impurities in Atomoxetine hydrochloride (cas 82248-59-7) with liquid chromatography using polysaccharide chiral stationary phases
Next:Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice07/24/2019
- Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial07/23/2019
- Conditioned place preference studies with atomoxetine in an animal model of ADHD: Effects of previous atomoxetine treatment07/22/2019
- Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease07/20/2019
- Determination of the enantiomer and positional isomer impurities in Atomoxetine hydrochloride (cas 82248-59-7) with liquid chromatography using polysaccharide chiral stationary phases07/19/2019
- Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat07/18/2019
- Atomoxetine prevents working memory loss in hyperactive rats, mediating plastic changes in prefrontal cortex pyramidal neurons07/17/2019
- Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder07/16/2019
- A quality by design approach to impurity method development for Atomoxetine hydrochloride (cas 82248-59-7) (LY139603)07/15/2019
-
Health and Chemical more >